☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
primary
Vifor and Angion's ANG-3777 Fail to Meet its Primary and Secondary Endpoint for Patients with High-Risk Kidney Transplant
October 27, 2021
Genentech's Ocrevus Shorter 2-Hour Infusion Receives the US FDA's Approval for Relapsing & Primary Progressive Multiple Sclerosis
December 15, 2020
Alnylam's Oxlumo (lumasiran) Receives the US FDA's Approval for Treatment of Primary Hyperoxaluria Type 1 in Pediatric and Adult P...
November 25, 2020
Sobi's Gamifant (emapalumab) Receives FDA Approval for Primary Haemophagocytic Lymphohistiocytosis (HLH)
November 10, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.